Ivan Cohen-Tanugi
Director/Board Member bei XBRANE BIOPHARMA AB
Profil
Ivan Cohen-Tanugi is the founder of Minerva Lifesciences GmbH.
He is currently an Independent Director at Xbrane Biopharma AB.
Previously, he served as the Chief Executive Officer of Eyevensys SAS, Kuros Biosciences Ltd., and Senior Vice President-International Operations at Stallergenes SA. He also worked as a Vice President at Amgen International AG.
Dr. Cohen-Tanugi holds an MBA from École des Hautes Études Commerciales de Paris and a doctorate from the University of Grenoble.
Aktive Positionen von Ivan Cohen-Tanugi
| Unternehmen | Position | Beginn |
|---|---|---|
| XBRANE BIOPHARMA AB | Director/Board Member | 16.05.2019 |
| Minerva Lifesciences GmbH | Founder | - |
Ehemalige bekannte Positionen von Ivan Cohen-Tanugi
| Unternehmen | Position | Ende |
|---|---|---|
| KUROS BIOSCIENCES AG | Chief Executive Officer | 04.12.2017 |
| Amgen International AG | Corporate Officer/Principal | - |
| STALLERGENES | Chief Operating Officer | - |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Chief Executive Officer | - |
Ausbildung von Ivan Cohen-Tanugi
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
| University of Grenoble | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| XBRANE BIOPHARMA AB | Health Technology |
| KUROS BIOSCIENCES AG | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Commercial Services |
| Amgen International AG | |
| Minerva Lifesciences GmbH |
